---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-326207"
form_type: "8-K"
ticker: "COO"
cik: "0000711404"
company_name: "COOPER COMPANIES, INC."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:19:00.622238+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CooperCompanies to acquire Generate Life Sciences for $1.6B cash, expected to close Q1 2022

## Summary
- CooperSurgical unit will acquire Generate, a provider of donor egg/sperm, fertility cryopreservation, and newborn stem cell storage.
- Aggregate cash consideration of $1.605 billion; transaction not subject to financing condition.
- Generate reported trailing twelve-month revenue of ~$250M as of Sep 30, 2021.
- Deal expected to be accretive to non-GAAP EPS by ~$0.30 in first year after closing, excluding one-time and amortization charges.
- Closing anticipated in Cooper's first fiscal quarter of 2022 (starting Nov 1), subject to HSR and customary conditions.

## SEC filing metadata
- accession: 0001193125-21-326207
- form_type: 8-K
- ticker: COO
- cik: 0000711404
- company_name: COOPER COMPANIES, INC.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/711404/000119312521326207/0001193125-21-326207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/711404/000119312521326207/d204711d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-326207
- JSON: https://secwatch.observer/filing/0001193125-21-326207.json
- Plain text: https://secwatch.observer/filing/0001193125-21-326207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.